Opia Technologies

Opia Technologies

Paris, France· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Opia Technologies is a Paris-based, private medical device company specializing in ophthalmology. It is building a portfolio of devices for sampling ocular surface components and for non-invasive ocular drug delivery, leveraging proprietary patents. The company operates a full-service model encompassing R&D, manufacturing, and regulatory services, and benefits from a strategic manufacturing partnership with JB TECNICS. Positioned at the intersection of diagnostics and therapeutic delivery, Opia aims to improve patient care in ocular surface diseases.

Ophthalmology

Technology Platform

Proprietary platform for minimally invasive sampling of ocular surface components (tear film, conjunctiva) and non-invasive ocular drug delivery via iontophoresis.

Opportunities

The high global prevalence of dry eye disease and other ocular surface disorders creates a large, growing market for improved diagnostic tools.
The shift towards personalized medicine and the poor bioavailability of traditional eye drops present a significant opportunity for Opia's sampling and iontophoresis-based drug delivery platforms.

Risk Factors

Key risks include regulatory hurdles in obtaining approval for novel medical devices in major markets, challenges in driving adoption among conservative ophthalmology practitioners, and competition from larger, established medical device and pharmaceutical companies with greater resources.

Competitive Landscape

Opia competes in the ocular diagnostics space with companies like TearLab (osmolarity) and others developing biomarker tests. In drug delivery, it faces competition from various sustained-release technologies and other iontophoresis devices. Its integrated service model and veterinary-first strategy provide distinct, but not unassailable, competitive angles.